This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (169)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Women's Health  • Menopause  • Alert me on articles by topic  Social Bookmarking   What's this?

Chi-Ling Chen, PhD; Noel S. Weiss, MD,DrPH; Polly Newcomb, PhD; William Barlow, PhD; Emily White, PhD

JAMA. 2002;287:734-741.

Context  Studies of long-term hormone replacement therapy (HRT) suggest an associated increased risk of breast cancer, but whether this association differs according to histologic type of cancer has not been extensively studied.

Objective  To determine whether the association between HRT and risk of breast cancer varies by HRT formulation and differs across histologic cancer types.

Design, Setting, and Participants  Nested case-control study among 705 postmenopausal women enrolled in the Group Health Cooperative of Puget Sound (GHC) who were aged 50 to 74 years and had primary invasive breast cancer diagnosed between July 1, 1990, and December 31, 1995 (cases), and 692 randomly selected aged-matched female members of GHC (controls).

Main Outcome Measure  Incidence and type of breast cancer by duration of HRT use in the 5-year period ending 1 year before diagnosis, which was ascertained from computerized pharmacy records.

Results  The incidence of breast cancer, all histologic types combined, was increased by 60% to 85% in recent long-term users of HRT, whether estrogen alone or estrogen plus progestin. Longer use of HRT (odds ratio [OR], 3.07 for 57 months or more; 95% confidence interval [CI], 1.55-6.06) and current use of combination therapy (OR, 3.91; 95% CI, 2.05-7.44) were associated with increased risk of lobular breast cancer. Long-term HRT use was associated with a 50% increase in nonlobular cancer (OR, 1.52 for 57 months or more; 95% CI, 1.01-2.29).

Conclusion  Our data add to the growing body of evidence that recent long-term use of HRT is associated with an increased risk of breast cancer and that such use may be related particularly to lobular tumors.

Author Affiliations: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, and Department of Epidemiology (Drs Chen, Weiss, Newcomb, and White), and Center for Health Studies, Group Health Cooperative, and Department of Biostatistics (Dr Barlow), University of Washington, Seattle.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

February 13, 2002
JAMA. 2002;287(6):785-786.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk
Reding et al.
Am J Epidemiol 2009;170:1241-1249.
ABSTRACT | FULL TEXT  

Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?
Fournier et al.
JCO 2009;27:5138-5143.
ABSTRACT | FULL TEXT  

The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004
Eheman et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1763-1769.
ABSTRACT | FULL TEXT  

Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort
Brinton et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:3150-3160.
ABSTRACT | FULL TEXT  

Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
Goodwin et al.
JCO 2008;26:1650-1656.
ABSTRACT | FULL TEXT  

Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-Defined Invasive Breast Cancer
Fournier et al.
JCO 2008;26:1260-1268.
ABSTRACT | FULL TEXT  

Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:43-50.
ABSTRACT | FULL TEXT  

Changes in Breast Cancer Incidence Rates in the United States by Histologic Subtype and Race/Ethnicity, 1995 to 2004
Li and Daling
Cancer Epidemiol. Biomarkers Prev. 2007;16:2773-2780.
ABSTRACT | FULL TEXT  

Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
Biglia et al.
Endocr Relat Cancer 2007;14:549-567.
ABSTRACT | FULL TEXT  

Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer
Zhang et al.
Am J Epidemiol 2007;165:524-529.
ABSTRACT | FULL TEXT  

The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes.
Bowe et al.
J Endocrinol 2006;191:399-405.
ABSTRACT | FULL TEXT  

Prospective breast cancer risk prediction model for women undergoing screening mammography.
Barlow et al.
JNCI J Natl Cancer Inst 2006;98:1204-1214.
ABSTRACT | FULL TEXT  

Genetic Bases of Estrogen-Induced Tumorigenesis in the Rat: Mapping of Loci Controlling Susceptibility to Mammary Cancer in a Brown Norway x ACI Intercross.
Schaffer et al.
Cancer Res. 2006;66:7793-7800.
ABSTRACT | FULL TEXT  

Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen et al.
Arch Intern Med 2006;166:1027-1032.
ABSTRACT | FULL TEXT  

Relationship between Established Breast Cancer Risk Factors and Risk of Seven Different Histologic Types of Invasive Breast Cancer.
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:946-954.
ABSTRACT | FULL TEXT  

A prospective study of female hormone use and breast cancer among black women.
Rosenberg et al.
Arch Intern Med 2006;166:760-765.
ABSTRACT | FULL TEXT  

Individualized Survival Curves Improve Satisfaction With Cancer Risk Management Decisions in Women With BRCA1/2 Mutations
Armstrong et al.
JCO 2005;23:9319-9328.
ABSTRACT | FULL TEXT  

Breast cancer risk with postmenopausal hormonal treatment
Collins et al.
Hum Reprod Update 2005;11:545-560.
ABSTRACT | FULL TEXT  

Medroxyprogesterone Acetate Induces Cell Proliferation through Up-Regulation of Cyclin D1 Expression via Phosphatidylinositol 3-Kinase/Akt/Nuclear Factor-{kappa}B Cascade in Human Breast Cancer Cells
Saitoh et al.
Endocrinology 2005;146:4917-4925.
ABSTRACT | FULL TEXT  

The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?
Genuis
J Am Board Fam Med 2005;18:419-425.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy, Percent Mammographic Density, and Sensitivity of Mammography
Kavanagh et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1060-1064.
ABSTRACT | FULL TEXT  

Age-Specific Incidence Rates of In situ Breast Carcinomas by Histologic Type, 1980 to 2001
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1008-1011.
ABSTRACT | FULL TEXT  

Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Colditz
Clin. Cancer Res. 2005;11:909s-917s.
ABSTRACT | FULL TEXT  

Prevention of Hormone-Related Cancers: Breast Cancer
Dunn et al.
JCO 2005;23:357-367.
ABSTRACT | FULL TEXT  

Clarifying the PROGINS Allele Association in Ovarian and Breast Cancer Risk: A Haplotype-Based Analysis
Pearce et al.
JNCI J Natl Cancer Inst 2005;97:51-59.
ABSTRACT | FULL TEXT  

Differential Regulation of Estrogen Receptor (ER){alpha} and ER{beta} in Primate Mammary Gland
Cheng et al.
J. Clin. Endocrinol. Metab. 2005;90:435-444.
ABSTRACT | FULL TEXT  

Comparison of Age-Specific Incidence Rate Patterns for Different Histopathologic Types of Breast Carcinoma
Anderson et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:1128-1135.
ABSTRACT | FULL TEXT  

Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial
Antoine et al.
Hum Reprod 2004;19:741-756.
ABSTRACT | FULL TEXT  

Antibiotic Use in Relation to the Risk of Breast Cancer
Velicer et al.
JAMA 2004;291:827-835.
ABSTRACT | FULL TEXT  

Increased Prevalence of the HFE C282Y Hemochromatosis Allele in Women with Breast Cancer
Kallianpur et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:205-212.
ABSTRACT | FULL TEXT  

Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population
Kerlikowske et al.
JCO 2003;21:4314-4321.
ABSTRACT | FULL TEXT  

Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years
Daling et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1175-1181.
ABSTRACT | FULL TEXT  

Risk of Mortality by Histologic Type of Breast Cancer Among Women Aged 50 to 79 Years
Li et al.
Arch Intern Med 2003;163:2149-2153.
ABSTRACT | FULL TEXT  

Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly
Ettinger
Arch Intern Med 2003;163:2237-2246.
ABSTRACT | FULL TEXT  

The Relationship between Alcohol Use and Risk of Breast Cancer by Histology and Hormone Receptor Status among Women 65-79 Years of Age
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1061-1066.
ABSTRACT | FULL TEXT  

Comprehensive Evaluation of the Older Woman
Amin et al.
Mayo Clin Proc. 2003;78:1157-1185.
ABSTRACT  

Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Travis et al.
JAMA 2003;290:465-475.
ABSTRACT | FULL TEXT  

Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial
Chlebowski et al.
JAMA 2003;289:3243-3253.
ABSTRACT | FULL TEXT  

Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer
Li et al.
JAMA 2003;289:3254-3263.
ABSTRACT | FULL TEXT  

Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword
Gann and Morrow
JAMA 2003;289:3304-3306.
FULL TEXT  

Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk
Wedren et al.
Carcinogenesis 2003;24:681-687.
ABSTRACT | FULL TEXT  

Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Li et al.
JAMA 2003;289:1421-1424.
ABSTRACT | FULL TEXT  

Pathophysiology and Treatment of Hot Flashes
Shanafelt et al.
Mayo Clin Proc. 2002;77:1207-1218.
ABSTRACT  

G Protein-Coupled Receptor 30 Is Critical for a Progestin-Induced Growth Inhibition in MCF-7 Breast Cancer Cells
Ahola et al.
Endocrinology 2002;143:3376-3384.
ABSTRACT | FULL TEXT  

Tamoxifen for breast cancer prevention: safety warning
Wooltorton
CMAJ 2002;167:378-379.
FULL TEXT  

American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
Chlebowski et al.
JCO 2002;20:3328-3343.
ABSTRACT | FULL TEXT  

Failure of Estrogen Plus Progestin Therapy for Prevention
Fletcher and Colditz
JAMA 2002;288:366-368.
FULL TEXT  

Postmenopausal Estrogen and Progestin Use in Relation to Breast Cancer Risk
Newcomb et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:593-600.
ABSTRACT | FULL TEXT  

Differences in Breast Cancer Hormone Receptor Status and Histology by Race and Ethnicity among Women 50 Years of Age and Older
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:601-607.
ABSTRACT | FULL TEXT  

Does HT Preferentially Increase Risk for Lobular Breast Carcinoma?
JWatch Women's Health 2002;2002:6-6.
FULL TEXT  

Hormone Replacement Therapy and Risk of Breast Cancer
Grant et al.
JAMA 2002;287:2360-2361.
FULL TEXT  

Hormone replacement therapy and the breast
MacLennan et al.
BMJ 2002;324:915-915.
FULL TEXT  

Hormone Replacement Therapy and Breast Cancer
JWatch General 2002;2002:6-6.
FULL TEXT